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Most Epstein-Barr virus (EBV)-positive tumor cells contain one of the latent forms of viral infection. The
role of lytic viral gene expression in EBV-associated malignancies is unknown. Here we show that EBV mutants
that cannot undergo lytic viral replication are defective in promoting EBV-mediated lymphoproliferative
disease (LPD). Early-passage lymphoblastoid cell lines (LCLs) derived from EBV mutants with a deletion of
either viral immediate-early gene grew similarly to wild-type (WT) virus LCLs in vitro but were deficient in
producing LPD when inoculated into SCID mice. Restoration of lytic EBV gene expression enhanced growth
in SCID mice. Acyclovir, which prevents lytic viral replication but not expression of early lytic viral genes, did
not inhibit the growth of WT LCLs in SCID mice. Early-passage LCLs derived from the lytic-defective viruses
had substantially decreased expression of the cytokine interleukin-6 (IL-6), and restoration of lytic gene
expression reversed this defect. Expression of cellular IL-10 and viral IL-10 was also diminished in lytic-
defective LCLs. These results suggest that lytic EBV gene expression contributes to EBV-associated lympho-
proliferative disease, potentially through induction of paracrine B-cell growth factors.
Epstein-Barr virus (EBV), a ubiquitous human herpes virus,
can infect cells in either a latent or lytic state. Viral latency is
characterized by the expression of a limited subset of viral
genes that encode the viral proteins currently known to be
required for EBV immortalization of primary B cells (45).
Entry into the viral lytic cycle is triggered by expression of
either of the two EBV immediate-early (IE) genes, BZLF1 and
BRLF1 (reviewed in reference 50). BZLF1 and BRLF1 func-
tion as transcriptional activators and initiate an ordered cas-
cade of viral lytic gene expression culminating in release of
infectious virus and usually death of the host cell. In addition,
BZLF1 and BRLF1 also activate expression of cellular genes
that are thought to assist the virus in modulating the host
immune response (4, 26, 28).
EBV is strongly associated with both B-cell and epithelial
cell malignancies (44). The fact that all EBV-associated ma-
lignancies have a predominantly latent pattern of viral gene
expression (44), coupled with studies demonstrating that sev-
eral viral latency proteins are absolutely required for transfor-
mation of B cells in vitro (17, 22, 49, 57), has led to the view
that only the latent phase of viral gene expression is important
during the development of EBV-associated malignancies. Nev-
ertheless, small numbers of lytically infected cells are fre-
quently detected in biopsies of EBV-associated lymphoprolif-
erative disease (LPD) in immunosuppressed individuals. One
study reported that 92% of biopsies from EBV-positive LPD in
immunosuppressed patients contained some tumor cells with
lytic viral gene expression (36). However, as lytically infected
cells are thought to die within a few days, such cells must be
constantly regenerated within EBV-positive LPD.
There are several potential mechanisms by which EBV lytic
gene expression could contribute to the growth of EBV-asso-
ciated LPD in vivo. By increasing the horizontal transmission
of the virus from cell to cell, lytic infection may increase the
total number of latently infected cells. In addition, viral lytic
genes, or cellular genes induced by viral lytic proteins, could
potentially encode paracrine factors that promote tumor growth.
For example, the Kaposi’s sarcoma herpesvirus (KSHV) lytic
protein ORF74 (where ORF is open reading frame) triggers
paracrine secretion of the angiogenic factor vascular endothelial
growth factor (2) and, thereby, may participate in the formation
of Kaposi’s sarcoma (35). Another KSHV lytic gene, viral in-
terleukin-6 (vIL-6), encodes a homolog of IL-6 (37) that may
function as a paracrine B-cell growth factor in KSHV-associ-
ated lymphomas (51).
EBV-associated LPD commonly occurs in immunosup-
pressed individuals following organ transplant (44) and dis-
plays a pattern of viral gene expression (latency III) that
closely resembles that of peripheral blood B cells transformed
by EBV in vitro (56). Lymphoblastoid cell lines (LCLs) ob-
tained from EBV-transformed B cells grow vigorously when
inoculated into SCID mice, providing an animal model for
LPD (47). Interestingly, there is increasing evidence that EBV-
immortalized LCLs are dependent on paracrine/autocrine se-
cretion of growth factors for optimal growth (3, 58). For ex-
ample, IL-6 enhances the growth of LCLs in mouse models
of LPD (48, 55), and some freshly explanted cells from
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EBV-positive LPD are dependent on autocrine/paracrine se-
cretion of IL-10 for growth and survival (30). Three different
EBV gene products, including the latent LMP1 and EBV-
encoded RNA gene products and the IE lytic protein, BZLF1,
have been reported to induce expression of cellular IL-10 (cIL-
10) (28) (24, 60). EBV also encodes a lytic viral homolog of
IL-10, vIL-10 (16), which likewise enhances the growth of B cells
(46). Deletion of vIL-10 from the EBV genome did not inhibit
EBV transformation of primary B cells or growth of LCLs in
SCID mice (54), although some studies have reported a contrib-
utory effect of vIL-10 on B-cell transformation (34, 53).
To determine whether lytic infection contributes to EBV-
induced LPD in SCID mice, we have examined the phenotype
of LCLs derived with wild-type (WT), BZLF1-deleted (Z-KO),
or BRLF1-deleted (R-KO) viruses (9), using peripheral blood
leukocytes from several different donors to generate LCLs.
The Z-KO and R-KO viruses cannot express most viral lytic
genes or replicate lytically unless the deleted gene product is
supplied in trans (9). Somewhat surprisingly, we show that
early-passage LCLs generated from the Z-KO and R-KO vi-
ruses (Z-KO and R-KO LCLs) are significantly impaired in
comparison to the corresponding WT LCLs in growth in SCID
mice. In contrast, acyclovir treatment (which prevents lytic
viral replication but not IE and early lytic viral gene expres-
sion) did not inhibit the growth of WT LCLs in SCID mice,
showing that release of infectious viral particles is not required
for efficient tumor formation in SCID mice. The early-passage
Z-KO and R-KO LCLs expressed substantially lower levels of
IL-6 and somewhat lower levels of cIL-10 than did the WT
LCLs, suggesting that the growth defect in SCID mice may be
due at least partially to the loss of essential paracrine B-cell
growth factors.
MATERIALS AND METHODS
EBV WT, Z-KO, and R-KO viruses and cell lines. 293 cells infected with the
R-KO virus, Z-KO virus, and WT virus have been described previously (9). In the
R-KO virus, nucleotides 103638 to 105083 (strain B95.8 coordinates, accession
number V01555) within the BRLF1 gene were removed via insertion of a tetra-
cycline resistance cassette. In the Z-KO virus, nucleotides 102389 to 103388
(B95.8 coordinates) within the BZLF1 gene were removed via insertion of a
kanamycin resistance cassette. The R-KO, Z-KO, and WT viruses also encode
enhanced green fluorescent protein and a hygromycin B resistance gene (both
cloned into the B95.8 deletion of EBV where the second copy of oriLyt normally
resides). LCLs containing the WT, Z-KO, and R-KO viruses were generated as
described previously (14), using the supernatant of BZLF1- or BRLF1-trans-
fected 293 cells infected with Z-KO or 293 R-KO virus, respectively, as a source
of virus and peripheral blood leukocytes derived from several different anony-
mous donors (obtained from the American Red Cross). LCLs were maintained
in RPMI medium supplemented with 10% fetal bovine serum (FBS) and anti-
biotics. Z-KO and R-KO LCLs were verified to be BZLF1 and BRLF1 via
PCR with BZLF1- and BRLF1-specific primers. LCLs used for in vitro and in
vivo experiments were considered “early-passage” LCLs if they were in culture
4 months following the initial transformation event.
Selection of BZLF1-expressing Z-KO cell lines. pREP9-Zp-Z (which contains
the BZLF1 gene driven by its own promoter) was generated by cloning the 1.8-kb
BamHI Z EBV fragment (strain B95.8 genome) into the BamHI site of a
modified pREP9 vector (Invitrogen) in which the Rous sarcoma virus (RSV)
promoter had been removed and a blasticidin resistance cassette inserted.
pREP9-RSV-Z (which contains the BZLF1 gene driven by the RSV long termi-
nal repeat promoter) was generated by cloning the KpnI/BglII fragment of the
pSG5-Z vector (a gift from S. D. Hayward) into the KpnI/BamHI site of a
modified pREP9 vector (pREP9-BSD) in which the G418 resistance cassette had
been replaced with a blasticidin resistance cassette. Both pREP9 plasmids con-
tain the EBV oriP element and hence can be stably maintained as episomes in
EBNA-1 expressing LCLs. Stable Z-KO LCL lines containing each vector were
generated using a nucleoporator (Amaxa) to transfect the cells as described
previously (14), followed by drug selection with 7 g/ml blasticidin (Invitrogen)
or 300 g/ml G418 (Gibco).
In vitro growth assays. Early-passage LCLs were seeded at 2  105 cells/ml in
RPMI medium supplemented with either 5% or 2% FBS and antibiotics. Ali-
quots were counted by trypan blue exclusion every 4 days, and cells were diluted
back to 2  105 cells/ml with fresh medium at each time point in order to
maintain log phase of growth.
In vivo LPD studies. Female SCID mice (6 to 8 weeks old; National Institutes
of Health) were maintained in a pathogen-free enclosure. A total of 5  106
early-passage LCLs in 150 l of sterile 1 phosphate-buffered saline were
injected subcutaneously into each flank. LPD size in three dimensions was
measured every 2 to 3 days once lesions became palpable. For acylovir (ACV;
American Pharmaceutical Partners, Inc.) studies, ACV was added to drinking
water at a final concentration of 5 mg/ml starting at day 2 postinjection and was
continued for the duration of the experiment. Based on previous studies, this
dose of ACV (between 1,333 and 1,666 mg per kg of body weight per day) would
result in mean plasma concentrations of between 6.4 and 10.9 g/ml (11). ACV
concentrations of 1.6 g/ml in human plasma inhibit oropharyngeal lytic infec-
tion during infectious mononucleosis (33, 59). Mice were euthanized when le-
sions were greater than 1 cm3 or mice appeared ill. All experiments were per-
formed in accordance with guidelines set forth by the Institutional Animal Care
and Use Committee of the University of North Carolina, Chapel Hill. P values
were calculated using an Excel t test.
Immunohistochemistry. Upon harvesting, LPD lesions were fixed in 10%
neutral-buffered formalin overnight, embedded in paraffin, and sectioned. Im-
munohistochemistry was performed using a BioGenex Super Sensitive non-
biotin horseradish peroxidase detection system using a BMRF1 antibody (1:200
dilution; Research Diagnostics, Inc.) or BZLF1 antibody (1:20 dilution; Argene).
Reverse-transcription PCR (RT-PCR) analysis. Total RNA was harvested
from LCLs growing in vitro and reverse transcribed as previously described (26).
Resulting cDNA was subjected to PCR using primers and conditions described
in Table 1.
Immunoblotting. Immunoblots were performed as previously described (14).
Primary antibodies used were as follows: LMP1 (CS1-4; dilution, 1:100; Dako),
-EBNA1 (1 g/ml; Abi;), -EBNA2 (1:100; Dako), -EBNA3A/-EBNA3B/
-EBNA3C (2 g/ml; Exalpha); -BZLF1 (1:100; Argene), -BRLF1 (1:100;
Argene), -BMRF1 (1:250; Vector Laboratories). Secondary antibodies were
horseradish-peroxidase-conjugated secondary anti-mouse (1:10,000; Promega)
or anti-sheep (1:5,000; Chemicon). Bound antibody was detected using the ECL
system (Amersham). For detection of lytic proteins, LCLs were grown at high
densities (1  106 cells/ml) for 48 h, which maximizes detection of lytic proteins
(unpublished observations). In addition, LCLs were treated with 5 g/ml meth-
otrexate (Immunex) for 48 h in order to induce lytic infection (10).
IL-6 and IL-10 ELISAs. LCLs (WT-, Z-KO-, or R-KO-derived) from the same
donor were plated at a density of 3  105 cells/ml in RPMI medium with 10%
FBS. Enzyme-linked immunosorbent assays (ELISAs) for IL-6 or IL-10 were
performed on the supernatants 2 days later using commercially available kits as
specified by the manufacturer (R&D Systems).
Apoptosis and cell viability assays. Early-passage LCLs were plated at a
concentration of 2  105 cells/ml in 100 l of RPMI medium (without phenol
red) supplemented with 2% FBS and antibiotics in a 96-well plate. Anti-Fas
antibody (clone CH11; Upstate) was added at 100 ng/ml. Cell viability was
assessed 48 h later using trypan blue exclusion (see Fig. 7b) or the Cell Prolif-
eration Kit II (Roche) (see Fig. 7a) according to the manufacturer’s instructions.
P values were calculated using an Excel t test.
RESULTS
Early-passage Z-KO and R-KO LCLs are impaired for
growth in SCID mice. As previously described (9), LCLs ob-
tained with the Z-KO, R-KO, and WT viruses grew at compa-
rable rates in vitro in medium supplemented with 5% serum
(Fig. 1a). Z-KO LCLs grew at a slightly slower rate than WT
and R-KO LCLs in medium supplemented with 2% serum
(Fig. 1b), but this difference was not statistically significant.
To examine whether lytic EBV infection contributes to the
generation of LPD in SCID mice, equal numbers of early-
passage (4 months in culture following the initial transfor-
mation event) Z-KO and WT LCLs, both derived from the
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same donor, were injected subcutaneously into the flanks of
SCID mice, and LPD development was monitored over time.
Unexpectedly, the Z-KO LCLs from this donor (donor 1)
formed LPD lesions at a significantly slower rate than WT
LCLs (Fig. 2a). To determine if this defect was unique to this
particular donor or Z-KO cell line, we generated WT and
Z-KO LCLs from two additional donors. As shown in Fig. 2b
and c, Z-KO LCLs derived from the two other donors also
grew more slowly when implanted into SCID mice than the
WT LCLs. Furthermore, early-passage R-KO LCLs derived
from two of the three donors (donors 1 and 3) also exhibited
an in vivo growth defect when compared to WT LCLs (Fig. 2d
and e). In contrast, one of the three R-KO LCL lines (from
donor 2) grew as well as the corresponding WT LCL (data not
shown).
During the course of these experiments, we noted that ex-
tensive in vitro passaging of WT LCLs allowed them to grow
more quickly (in comparison to the early-passage WT LCLs)
when injected into SCID mice (data not shown). Interestingly,
Z-KO and R-KO LCLs, which were clearly defective in com-
parison to the corresponding WT LCLs for growth in SCID
mice when tested at early passage (within 4 months of immor-
talization), also acquired enhanced growth capacity in SCID
mice with extended passaging in vitro and eventually became
similar to the WT LCLs (data not shown). Thus, the growth
defect of the Z-KO and R-KO LCLs was most apparent in
newly derived lines.
These results suggested that one or more aspects of lytic
EBV infection contribute to the growth of early-passage LCLs
in SCID mice. To determine if the release of infectious viral
FIG. 1. Z-KO and R-KO LCLs grow at a similar rate to WT LCLs in vitro. Early-passage WT, Z-KO, or R-KO LCLs were plated in medium
containing either 5% (a) or 2% (b) FBS. Cells were counted every 4 days, and at each time point the cells were diluted back to 2  105 cells/ml
to maintain log phase growth. The experiment was done in duplicate with mean total cells plotted on the y axis; error bars indicate standard
deviation. Similar results were obtained in samples from two different donors; one representative donor is shown.
TABLE 1. RT-PCR primers and conditions
Genea Primer sequence (5–3) Ta(°C)b Cycles Reference
LMP2A F: AGGAACGTGAATCTAATGAAGA 55 38 61
R: AAGTGACAACCGCAGTAAGCA
EBER1 F: AAAACATGCGGACCACCAGC 55 25 61
R: AGGACCTACGCTGCCCTAGA
EBNA-LP F: AGAGGAGGAGGTGGTAAGCGGTTC 55 30 61
R: CTGGCTAAGCCTGTGACTTAG
BZLF1 F: CACGGTAGTGCTGCAGCAGTTGC 61 30
R: CCCAGAATCAACAGACTAACCAAGCCG
BRLF1 F: GCCATGAGGCCTAAAAAGGATGGC 56 30
R: GCCCAGCACCTTGCTGTAGGTGTA
VIL-10 F: CGAAGGTTAGTGGTCACTCT 52 35 34
R: CACCTGGCTTTAATTGTCATG
BHRF1 F: GTCAAGGTTTCGTCTGTGTG 55 40 13
R: TTCTCTTGCTGCTAGCTCCA
CIL-10 F: CTGAGAACCAAGACCCAGACATCAAGG 61 35 28
R: CAATAAGGTTTCTCAAGGGGCTGGGTC
IL-6 F: CCACTCACCTCTTCAGAA 49 35 40
R: GCGCAGAATGAGATGAGT
TGF-	 F: GCTGCACTTGCAGGAGCGCAC 52 30 43
R: AAATGGATCCACGAGCCCAA
B2-microglobulin F: TTCTGGCCTGGAGGGCATCC 56 23 32
R: ATCTTCAAACCTCCATGATG
a EBNA-LP, Epstein-Barr virus nuclear antigen leader protein; TGF-	, transforming growth factor 	.
b Ta, annealing temperature.
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particles is required for this effect, mice injected with WT
LCLs were treated with or without the antiviral drug ACV,
which inhibits the late phase of lytic replication without affect-
ing the expression of IE or early lytic viral genes. ACV did not
impair the growth of WT LCLs in SCID mice (data not
shown). These results suggest that early lytic viral gene expres-
sion, but not the release of infectious viral particles, contrib-
utes to the enhanced growth of the early-passage WT LCLs in
SCID mice.
BZLF1 expression rescues the in vivo growth defect of Z-KO
LCLs in SCID mice. To ensure that the in vivo phenotype
observed with the Z-KO LCLs was due to the lytic-defective
state of the Z-KO LCLs, we determined whether restoration of
BZLF1 expression in the Z-KO LCLs would reverse the phe-
notype in SCID mice. The BZLF1 gene was cloned under the
control of its own promoter (donor 1) or the RSV promoter
(donor 2) into the oriP-containing vector, pREP9, which can be
stably maintained in EBV-positive cells as an episome. Z-KO
LCLs stably expressing BZLF1 (or the vector control) were
selected and amplified in vitro over a period of 
2 months, and
then tested for the ability to form LPD when injected into
SCID mice. As shown in Fig. 3a and b, the growth-defective
phenotype of Z-KO LCLs was somewhat attenuated by the
number of in vitro passages required to select for stable cell
lines. Nevertheless, Z-KO LCLs in which the BZLF1 gene was
reexpressed under its own promoter or the RSV promoter, in
the pREP9 vector clearly grew significantly faster than Z-KO
LCLs carrying the vector control.
Immunohistochemical staining of the tumors was performed
to compare the amount of lytic EBV gene expression in LPD
lesions derived from WT LCLs, Z-KO LCLs carrying the con-
trol vector, or Z-KO LCLs carrying a BZLF1 expression vec-
tor. Expression of the lytic genes BZLF1 and BMRF1 was
observed in approximately 1% of cells in the LPD lesions
derived from WT LCL, whereas the LPD lesions derived from
the Z-KO LCLs carrying the control vector, as expected, had
no detectable lytic EBV gene expression (Fig. 3c and d). LPD
lesions derived from the Z-KO LCLs carrying the BZLF1
expression vector (using the endogenous promoter) had a sim-
ilar level of expression of the lytic genes BZLF1 and BMRF1
FIG. 2. Early-passage Z-KO and R-KO LCLs are impaired for
growth in SCID mice. Early-passage WT, Z-KO, or R-KO LCLs were
injected subcutaneously into the flanks of SCID mice, and LPD growth
was monitored. y axis, mean LPD size in cubic millimeters; x axis, day
postinjection. Error bars indicate standard error of the mean. (a) WT
versus Z-KO LCL LPD growth (donor 1; eight injection sites per
condition). (b) WT versus Z-KO LCL LPD growth (donor 2; eight in-
jection sites per condition). (c) WT versus Z-KO LPD growth (donor 3;
eight injection sites per WT condition and four injections sites per
Z-KO condition). (d) WT versus R-KO LCL LPD growth (donor 1;
eight injection sites per WT condition and four injection sites per
R-KO condition). (e) WT versus R-KO LCL LPD growth (donor 3;
eight injection sites per condition).
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FIG. 3. BZLF1 expression rescues the in vivo defect of Z-KO LCLs in SCID mice. Z-KO LCLs carrying a control vector (Z-KO-vector) or a
BZLF1 expression vector driven by the endogenous BZLF1 promoter (Z-KO-ZpZ) (a) or a BZLF1 expression vector driven by the RSV promoter
(Z-KO-RSV-Z) (b) were injected subcutaneously into the flanks of SCID mice, and LPD growth was monitored over time. y axis, mean LPD size
in cubic millimeters; x axis, day postinjection. Error bars indicate standard error of the mean. Data shown in panel a represent the mean of six
injection sites per condition for Z-KO-vector and Z-KO-ZpZ LCLs from donor 1. Data shown in panel b represent the mean of eight injection
sites per condition for Z-KO-vector and Z-KO-RSV-Z LCLs from donor 2. (c) BZLF1 immunohistochemistry of LPD harvested from WT
LCL-injected mice (WT), Z-KO-vector LCL-injected mice (Z-KO-vector), or Z-KO-ZpZ LCL-injected mice (Z-KO-ZpZ). Arrows indicate
positively staining cells. (d) BMRF1 immunohistochemistry of LPD harvested from WT LCL-injected mice (WT), Z-KO-vector LCL-injected mice
(Z-KO-vector), or Z-KO-ZpZ LCL-injected mice (Z-KO-ZpZ). Arrows indicate positively staining cells.
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as the LPD lesions derived from WT LCLs (Fig. 3d). Other
than the differences in LPD size and lytic EBV gene expres-
sion, no other obvious differences were observed between the
WT versus Z-KO-derived LPD as assessed by hematoxylin and
eosin staining (data not shown).
Viral gene expression in Z-KO, R-KO, and WT LCLs. La-
tent viral gene expression was examined using both RT-PCR
analysis and Western blotting (Fig. 4). Latent gene expression
between WT, Z-KO, and R-KO LCLs was comparable among
all latency genes, with the exception that the Z-KO LCLs
expressed a truncated form of LMP1. Sequencing revealed that
this truncated form of LMP1 was due to an in-frame deletion
of residues 254 to 302 (data not shown). This region of LMP1,
encoded by a variable number of a repeated sequence, was
previously shown to be dispensable for EBV immortalization
of B cells (6, 18) and does not overlap either of the essential
signaling/transforming motifs of LMP1 (CTAR1 and CTAR2)
(19, 20). As the R-KO LCLs, which express full-length LMP1,
were also impaired for growth in SCID mice and reexpression
of BZLF1 in the Z-KO LCLs rescued the in vivo phenotype,
this LMP1 deletion is unlikely to contribute to the in vivo
growth defect of the Z-KO and R-KO LCLs.
The WT LCLs expressed both the BZLF1 and BRLF1 IE
lytic genes (Fig. 4a and c). As expected, neither the Z-KO
nor R-KO LCLs had detectable expression of their deleted
genes (Fig. 4a). However, in contrast to the completely
latent phenotype of these mutants in 293 cells (14), Z-KO
LCLs expressed BRLF1 at the RNA level, and R-KO LCLs
expressed BZLF1 at both the RNA and protein level
(Fig. 4a). Both the Z-KO and R-KO LCLs had dramatically
decreased expression of the early lytic gene, BHRF1 (Fig. 4a),
which encodes a bcl-2 homolog (29), the early lytic gene,
BMRF1 (Fig. 4c), and the late lytic gene, vIL-10 (Fig. 4a), in
comparison to the WT LCLs.
Early-passage Z-KO and R-KO LCLs express lower levels of
IL-6 and cIL-10 in vitro. We next examined whether early-
passage Z-KO and R-KO LCLs had reduced expression of the
B-cell paracrine growth factors IL-6 and cIL-10 in comparison
to WT LCLs by using semiquantitative RT-PCR techniques
(Fig. 5a). Expression of IL-6 was markedly decreased in both
the Z-KO and R-KO LCLs derived from two different donors
FIG. 4. Viral gene expression in Z-KO, R-KO, and WT LCLs. (a)
Analysis of viral gene expression in Z-KO, R-KO, and WT LCLs
growing in vitro using RT-PCR analysis. Similar results were obtained
in samples from two different donors; one representative donor is
shown. To account for potential contamination by genomic DNA in
the PCR, control reactions containing RNA not transcribed with
reverse transcriptase were included (RT). Serial dilutions of the
cDNAs were also subjected to PCR analysis using primers for
B2-microglobulin (B2-micro) as a loading control. (b) Analysis of la-
tent viral gene expression using immunoblot analysis of total protein
from LCLs growing in vitro. BL30() is an EBV-negative Burkitt
lymphoma line. (c) Analysis of lytic viral gene expression of total
protein from LCLs growing in vitro. WT LCLs treated with the lytic
inducing agent methotrexate (WTMTX) were included as a positive
control for lytic protein expression.
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in comparison to the corresponding WT LCLs. Z-KO and
R-KO LCLs derived from two different donors also had de-
creased expression of cIL-10 in comparison to the correspond-
ing WT LCLs (Fig. 5a). In contrast, although BZLF1 was
previously shown to activate transforming growth factor 	 ex-
pression when expressed from a heterologous promoter in
HeLa cells (4), transforming growth factor 	 expression was
similar in WT, Z-KO, and R-KO LCLs. Importantly, reestab-
lishment of BZLF1 expression in the Z-KO LCLs increased
IL-6 and cIL-10 expression, as well as vIL-10 expression
(Fig. 5b), confirming that the defects in cIL-10, IL-6, and
vIL-10 mRNA expression were indeed secondary to the loss of
lytic EBV gene expression.
To confirm that lytic-defective LCLs secrete less IL-6 and
cIL-10 than the corresponding WT LCLs, ELISAs were per-
formed to quantitate the amount of IL-6 and IL-10 in the
supernatants of WT, Z-KO, and R-KO LCLs derived from the
same donor. The supernatants from each of the three Z-KO
LCLs contained considerably less IL-6 than the supernatants
of the corresponding WT LCL (Fig. 6a and data not shown).
Furthermore, restoration of BZLF1 expression in the Z-KO
LCLs resulted in enhanced IL-6 secretion (Fig. 6b). Superna-
tants from two of the three R-KO LCLs also had reduced IL-6
in comparison to the WT LCLs (Fig. 6b and data not shown).
Interestingly, the R-KO LCL derived from donor 2, which was
the only R-KO LCL able to grow as efficiently as the WT LCL
in SCID mice, expressed as much IL-6 as the corresponding
WT LCL (data not shown).
The supernatants of the Z-KO LCLs and two of the three
R-KO LCLs also had reduced amounts of cIL-10 in compari-
son to the WT LCLs (Fig. 6c and data not shown), although
this effect was not as striking as the reduction of IL-6. As was
the case for IL-6, the R-KO LCL from donor 2 was found to
have a similar level of cIL-10 as the corresponding WT LCL
(data not shown). Restoration of BZLF1 expression in the
Z-KO LCLs increased the amount of cIL-10 in the supernatant
(Fig. 6d). These results suggest that the in vivo growth defects
of the early-passage Z-KO and R-KO LCLs may be due to
diminished IL-6 and, to a lesser extent, cIL-10 secretion in
comparison to the corresponding WT LCLs.
Z-KO LCLs are more sensitive than WT LCLs to Fas-
induced apoptosis in vitro. We also examined whether early-
passage Z-KO or R-KO LCLs are more susceptible than
WT-LCLs to Fas-mediated apoptosis, as both Z-KO and
R-KO LCLs do not express the antiapoptotic lytic viral gene,
BHRF1 (Fig. 4). Z-KO LCLs derived from two different do-
nors exhibited a statistically significant increase in the percent-
age of cells killed following treatment with anti-Fas antibody in
comparison to the corresponding WT LCLs (Fig. 7a), and this
effect was reversed when BZLF1 was expressed in the Z-KO
LCLs (Fig. 7b). However, no difference was noted between
R-KO and WT LCLs, suggesting that the enhanced sensitivity
of the Z-KO LCLs to apoptotic stimuli is not due to decreased
BHRF1 but, instead, may reflect an antiapoptotic effect medi-
ated directly by the BZLF1 protein. The level of Fas expression
in WT versus lytic-defective LCLs was similar (data not
shown).
DISCUSSION
In this paper we have examined the potential role of lytic
viral gene expression in the development of EBV-induced
LPD. We show that LCLs generated with lytic-defective
viruses grow similarly to WT LCLs in vitro but at early passage
are significantly impaired in their ability to form LPD in SCID
mice. Furthermore, restoration of lytic gene expression in
LCLs derived from lytic-defective viruses enhances their
growth in SCID mice. As the lytic-defective LCLs also had
decreased expression of several B-cell growth factors, in par-
ticular IL-6, which are known to be important for LCL growth
in SCID mice (3, 46, 48, 55, 58), our results suggest that a small
number of lytically infected cells contributes to the growth of
the latently infected cells in LPD by inducing the release para-
crine B-cell growth factors. In addition, as shown in the ac-
FIG. 5. Early-passage Z-KO and R-KO LCLs express lower levels of IL-6 and cIL-10 mRNA in vitro than the corresponding WT LCLs. (a)
Total RNA from early-passage LCLs growing in vitro was subjected to RT-PCR analysis. Similar results were obtained in samples from two
different donors; one representative donor is shown. RT, no reverse transcriptase control. Serial dilutions of the cDNAs were also subjected to
PCR analysis using primers for B2-microglobulin (B2-micro) as a loading control. (b) RT-PCR of RNA harvested from Z-KO LCLs carrying a
control vector (Z-KO-vector) or a BZLF1-expression vector (Z-KO-RSV-Z).
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companying paper (15), lytic-defective LCLs also secrete less
vascular endothelial growth factor than the WT LCLs and
cannot support angiogenesis in vitro. Thus, lytically infected
cells in EBV-positive tumors may contribute to tumor forma-
tion through the release of paracrine growth factors as well as
angiogenesis factors.
Early-passage Z-KO and R-KO LCLs expressed lower levels
of the B-cell growth factors IL-6, cIL-10, and vIL-10 than
FIG. 6. Supernatants of early-passage Z-KO and R-KO LCLs have lower levels of IL-6 and cIL-10 in vitro than the corresponding WT LCLs.
The amount of IL-6 and cIL-10 in the supernatants of early-passage LCLs growing in vitro was quantitated by ELISA as described in Materials
and Methods. Similar results were obtained from the Z-KO LCLS in samples from three different donors; results from representative donors are
shown. Similar results from the R-KO LCLs were obtained in two out of three donors as discussed in the text. (a) IL-6 levels in the supernatants
of WT, Z-KO, and R-KO LCLS. Results are normalized such that the amount of IL-6 in each WT LCL supernatant is set at 100%. (b) IL-6 levels
in the supernatants harvested from Z-KO LCLs carrying a control vector (Z-KO-vector) or a BZLF1-expression vector (Z-KO-RSV-Z). Results
are normalized such that the amount of IL-6 in the supernatant of Z-KO LCLs carrying the control vector is set at 100%. (c) IL-10 levels in the
supernatants of WT, Z-KO, and R-KO LCLS Results are normalized such that the amount of IL-10 in each WT LCL supernatant is set at 100%.
(d) IL-10 levels in the supernatants harvested from Z-KO LCLs carrying a control vector (Z-KO-vector) or a BZLF1-expression vector
(Z-KO-RSV-Z). Results are normalized such that the amount of IL-10 in the supernatant of Z-KO LCLs carrying the control vector is set at 100%.
FIG. 7. Z-KO LCLs are more sensitive than WT LCLs to Fas-induced apoptosis in vitro. (a) Early-passage Z-KO, R-KO, or WT LCLs from
two different donors were subjected to treatment with anti-Fas antibody for 48 h. Following treatment, cell viability was assessed as described in
Materials and Methods. Data shown represent the mean of a representative experiment done in triplicate; error bars indicate standard deviation.
(b) WT LCLs, Z-KO LCLs carrying a control vector (Z-KO-vector), and Z-KO LCLs carrying a BZLF1 expression vector (Z-KO-ZpZ) were
subjected to anti-Fas treatment, followed by an assessment of viability. Data shown represent the mean of a representative experiment done in
duplicate; error bars indicate standard deviation.
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WT LCLs. Furthermore, this decrease in IL-6, cIL-10, and
vIL-10 expression in Z-KO LCLs was reversed when BZLF1
was expressed in trans. Both cIL-10 and IL-6 have already been
heavily implicated in the development of EBV-positive LPD,
both in transplant patients (12, 23, 25) and in mouse models of
EBV LPD (1, 3, 7, 31, 34, 39, 48). Most compellingly, when 12
patients with transplant-associated LPD were treated with an
anti-IL-6 antibody, 8 of the patients had a remission or cure of
the disease (12). In addition to the paracrine growth effects of
cIL-6 and cIL-10, the virally encoded homologue of cIL-10,
vIL-10, has also been shown to enhance viral transformation of
B cells in vitro (34, 53) and to stimulate growth of B cells (46).
Thus, the decrease in both cIL-10 and vIL-10 expression which
occurs in the Z-KO and R-KO LCLs may have a greater
impact on LPD growth in SCID mice than was previously
observed using LCLs immortalized with a vIL-10-deleted
EBV (12).
While early-passage LCLs derived from either the Z-KO or
R-KO viruses were impaired for growth in SCID mice, the
phenotype of the Z-KO LCLs was somewhat more severe.
Although the R-KO LCLs formed tumors poorly in two dif-
ferent donors (Fig. 2), we identified one donor in which the
Z-KO, but not R-KO, LCL was deficient in tumor growth
(unpublished data). The efficiency at which EBV LPD devel-
ops in SCID mice is highly donor dependent (21, 38, 42). We
speculate that BZLF1 is more important than BRLF1 for ac-
tivation of cIL-10 and IL-6. Polymorphisms in the human IL-10
and IL-6 promoters affect their expression (5, 8), and LCLs
derived from donors with higher constitutive levels of IL-6
and/or cIL-10 may be less dependent upon BZLF1-activated
cytokine production. Of note, the one R-KO LCL (derived
from donor 2) that grew efficiently in SCID mice at early
passage was also the only R-KO LCL that expressed IL-6 and
cIL-10 at a level similar to that of the corresponding WT LCL.
Thus, the level of IL-6 and IL-10 expression in early-passage
Z-KO and R-KO LCLs in comparison to the corresponding
WT LCL was highly correlated with their ability to grow as
efficiently as the WT LCL when injected into SCID mice.
Although we believe that the defective phenotype of early-
passage lytic-defective LCLs is due to the loss of lytic viral
protein expression, during the course of these studies we dis-
covered that the Z-KO virus has a small in-frame deletion in
the LMP1 gene. This small LMP1 deletion, which was ob-
served in the Z-KO but not R-KO LCLs, is clearly not impor-
tant for in vitro transformation of B cells but could conceivably
contribute to the impaired growth of the Z-KO LCLs in SCID
mice. However, as restoration of BZLF1 expression alone in
trans was sufficient to enhance the growth of Z-KO LCLs, this
suggests that the growth defect of Z-KO LCLs in SCID mice is
due solely or primarily to the lack of lytic gene expression.
Another possible mechanism by which lytic EBV gene ex-
pression could contribute to LPD growth would be virally
mediated resistance to apoptosis. Consistent with this, Z-KO
LCLs were more sensitive to Fas-induced cytotoxicity than the
WT LCLs, and this defect was reversed when BZLF1 was
expressed in trans. This phenotype in the Z-KO LCLs was
unlikely due to loss of BHRF1 expression, as the R-KO LCLs
also had no BHRF1 expression and did not have enhanced
apoptosis in response to Fas. BZLF1 itself may have an anti-
apoptotic effect in some circumstances, consistent with its abil-
ity to inhibit p53 function (32). If so, the BZLF1 expressed in
R-KO LCLs may be sufficient to mediate this antiapoptotic
effect.
While our results are most applicable to EBV-induced LPD,
whether lytic infection contributes to other types of EBV-
associated lymphomas (or epithelial cell tumors) remains un-
known. Although EBV-positive Burkitt lymphomas also con-
tain a portion of cells with lytic infection (62), lytically infected
cells are rarely found in EBV-positive Hodgkin’s disease (41).
Our finding that lytic-defective LCLs maintained in culture for
many passages eventually regained the ability to grow effi-
ciently in SCID mice suggests that lytic EBV infection may be
more important during the early stages of LPD and probably
becomes unnecessary as tumor cells are selected for with ad-
ditional growth-promoting alterations.
Interestingly, much of the anti-EBV cytotoxic T-cell re-
sponse is directed against lytic viral antigens (52). Our results
suggest that the decreased ability of immunosuppressed hosts
to control the lytic form of EBV may promote the development
of LPD not only by allowing enhanced horizontal transmission
of the virus but also by increasing the number of lytically
infected tumor cells. In addition, novel drugs that inhibit IE or
early viral gene expression, rather than the later step of viral
replication, could potentially be useful for decreasing EBV-
induced LPD in high-risk patients. Agents that block fatty acid
synthase activity were recently shown to inhibit early lytic EBV
gene expression (27) and thus might be useful in this regard.
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